CORNELIUS GROUP PLC

Risk Rating: MEDIUM Justification: While CORNELIUS GROUP PLC benefits from a long operating history and current compliance status, the severe concentration of control in a single individual for a Public Limited Company, combined with notable administrative discrepancies in the Companies House register and a complete absence of financial performance data in the provided records, prevents a lower rating. The inability to assess solvency and liquidity metrics based on the current dataset necessitates a cautious stance.

Key Concerns: * Concentrated Ownership and Key-Person Risk: Dr. Neville Douglas Prior holds between 50% and 75% of the company's shares and voting rights, alongside the right to appoint and remove directors. For a PLC, this level of concentrated control significantly limits minority shareholder influence and creates substantial key-person risk should the primary controller become unavailable or face personal financial distress. * Administrative and Data Anomalies: The officer register contains duplicate entries for key individuals (Dr. Prior appears multiple times with slight formatting variations; Phillip Timothy Gibbons is listed twice with a spelling variation of his middle name). Additionally, the accounts and confirmation statement dates appear to be future-dated (e.g., accounts made up to 2026-01-31). These discrepancies suggest potential administrative sloppiness or data synchronization issues that could mask underlying governance weaknesses. * Financial Opacity: The provided data lacks crucial financial metrics (Current Assets, Current Liabilities, Net Assets, P&L Reserve). The only financial figure available is a stated share capital of £423, which is likely a nominal statutory figure rather than a reflection of actual equity. Without visibility into leverage, working capital, or profitability, solvency and liquidity risks cannot be quantified.

Positive Indicators: * Long Corporate Lineage: Incorporated in 1985, the company has survived multiple economic cycles, suggesting operational resilience and a stable market position within the wholesale chemical products sector. * Filing Compliance: Despite the date anomalies in the dataset, the filings are explicitly marked as "NO" for overdue, indicating that the company is currently maintaining its statutory filing requirements with Companies House. * Structured Board: The officer roster indicates a mix of executive leadership (including a designated Finance Director) and non-executive oversight (Non-Executive Directors), which is a positive governance signal for a company of this size and category.

Due Diligence Notes: * Financial Statement Retrieval: Urgently acquire the latest full filed accounts (given its Group/PLC status, these should be available) to calculate solvency ratios, assess working capital position, and verify the P&L reserve and net assets position. * Officer Register Reconciliation: Investigate the duplicate and variant entries for Dr. Prior and Mr. Gibbons on the Companies House register to ensure there are no unresolved compliance issues or unauthorized appointments. * Date Discrepancy Verification: Clarify the future-dated accounts and confirmation statement data (made up to 2026 and 2025 respectively). Determine if this is a data extraction error or if there is a legitimate reason for the dates, which could indicate a recent corporate action or restructuring. * Board Activity Verification: Review the current engagement status of directors listed with unconventional titles (e.g., Richard John Herring noted as "Retired" and Joanne Stephenson noted as "Marketing Consultant") to ensure the board is actively governing and meeting fiduciary duties. * PSC Verification: Confirm the nature of Dr. Prior's control and whether his dominance over the board composition has historically led to related-party transactions or conflicts of interest, which should be detailed in the notes of the annual accounts.